Skip to main content

Table 1 Patient characteristics between non-transplant group and transplant group

From: Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study

   

P

Characteristics

Non-transplant (n= 67)

Transplant (n = 55)

Non-transplant vs transplant

Gender, n (%)

  

0.153

 Male

34 (50.7)

35 (63.6)

 

 Female

33 (49.3)

20 (36.4)

 

Age, years

  

0.332

 Median (range)

27 (9, 65)

26 (3, 65)

 

Hyperploidy, n (%)

3 (4.5)

3 (5.5)

0.804

Hypoplodiy, n (%)

1 (1.5)

1 (1.8)

0.888

Complex karyotype, n (%)

4 (6.0)

2 (3.6)

0.553

iAMP 21a, n (%)

1 (1.5)

1 (1.8)

0.888

ETV6-RUNX1, n (%)

1 (1.5)

0 (0)

0.363

E2A-PBX1, n (%)

1 (1.5)

0 (0)

0.363

MYC mutation, n (%)

1 (1.5)

0 (0)

0.363

HOX11 mutation, n (%)

1 (1.5)

0 (0)

0.363

KMT2A rearranged, n (%)

3 (4.5)

5 (9.1)

0.306

BCR-ABL1, n (%)

11 (16.4)

11 (20.0)

0.609

Ph like, n (%)

1 (1.5)

4 (7.3)

0.109

IgH rearranged, n (%)

1 (1.5)

0 (0)

0.363

IKZF1 mutation, n%

3 (4.5)

7 (12.7)

0.098

Poor-risk cytogeneticsb, n (%)

18 (26.9)

21 (38.2)

0.182

Good-risk cytogeneticsc, n (%)

2 (3.0)

2 (3.6)

0.841

Primary refractory to chemotherapy, n (%)

17 (25.4)

21 (38.2)

0.128

Total number of relapses before CAR-T

  

0.405

 Median (range)

1 (0, 6)

1 (0, 3)

 

Prior lines of therapy

  

0.888

 Median (range)

4 (2, 15)

3 (2, 9)

 

 Prior allo-HSCT, n (%)

22 (32.8)

3 (5.5)

< 0.001

 Extramedullary infiltration, n (%)

9 (13.4)

3 (5.5)

0.141

Platelet count before CAR-T, 109/L

  

0.339

 Median (range)

130 (15, 412)

140 (12, 389)

 

PLT < 1*LLN before CAR-T, n (%) (n = 66 + 52)

28 (42.4)

15 (28.8)

0.128

LDH > 1*ULN before CAR-T, n (%) (n = 66 + 52)

26 (39.4)

25 (48.1)

0.345

Blast cells in bone marrow before CAR-T

  

0.766

 Median (range)

22.5% (0, 97.0%)

16.0% (0, 90.0%)

 

CAR-T cell dose, 106/kg

  

0.853

 Median (range)

3.0 (0.3, 25.0)

5.0 (0.1, 30.4)

 

Source of CAR-T cells, n (%)

  

0.002

 Autologous

44 (65.7)

50 (90.9)

 

 Recipient-derived allogenic

15 (22.4)

3 (5.5)

 

 Donor-derived allogenic

7 (10.4)

0 (0)

 

 Third-party

1 (1.5)

2 (3.6)

 
  1. aiAMP21 intrachromosomal amplification of chromosome 21
  2. bPoor-risk cytogenetics are defined as hypodiploidy, KMT2A rearranged, t(v;14q23)/IgH rearranged, t(9;22)(q34;q11.2): BCR-ABL1, complex karyotype, Ph-like, and iAMP21
  3. cGood-risk cytogenetics are defined as hyperdiploidy, and t(12;21)(p13;q22): ETV6-RUNX1